Covalon Technologies Ltd. (TSXV:COV)

Market Cap	93.07M +47.6%
Revenue (ttm)	34.35M +4.1%
Net Income	4.39M +89.7%
EPS	0.16 +84.9%
Shares Out	27.62M
PE Ratio	21.16
Forward PE	17.51
Dividend	0.15 (4.55%)
Ex-Dividend Date	Nov 4, 2025

Volume	3,207
Open	3.360
Previous Close	3.370
Day's Range	3.340 - 3.360
52-Week Range	1.550 - 3.590
Beta	0.14
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About Covalon Technologies

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, the Middle East, Canada, Latin America, Asia, and internationally. The company’s platform technologies comprises collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secon...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2004
• Employees: 37
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: COV

Financial Performance

In fiscal year 2025, Covalon Technologies's revenue was 32.82 million, an increase of 5.29% compared to the previous year's 31.17 million. Earnings were 2.06 million, a decrease of -22.91%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 10, 2026

Data Sources Report a data error